Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib treatment, mice showed significant reduction in lung infiltration and fibrosis, improved clinical scores, reduced vascular smooth muscle hypertrophy, and lower right ventricular systolic blood pressure. These results were validated in a second bleomycin lung injury model.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
4027 Views
Comment
Sign in to post a comment